Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls
- PMID: 20863009
- DOI: 10.1055/s-0031-1296321
Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls
Abstract
Purpose: In an open observational prospective multicentered study on a cohort of patients with a creatinine clearance of < or = 65 ml/min and diagnosed with the "Esslinger Fall Risk Assessment" to be at an increased risk for falls the effect of daily treatment with 1 microg alfacalcidol (CAS 41294-56-8; Alpha-D3) on muscle power, balance and number of fallers and falls was investigated.
Methods: In this open prospective study on 237 participants recruited in Germany, 16.9% men and 83.1% women with a mean age of 75.9 years and a mean body mass index (BMI) of 26.3 kg/m2 underwent at the beginning and after 3 and 6 months different muscle strength and balance tests such as the Timed-up and Go Test (TUG), the Tandem Stand Test (TST) and the Chair Rising Test (CRT). A successful performance in these tests has been associated with a significantly lower risk for falls and non-vertebral fractures in elderly patients (successful test performance: TUG < 12 s, TST > 10 s, CRT < 10 s).
Results: Controlled for age, gender and BMI, treatment with alfacalcidol was associated with a significantly increased performance in all three muscle and balance tests already after 3 months. This effect increased after six months of therapy and a significant increase in the number of participants who were able to successfully perform the different tests was observed: plus 74.9% for the TUG (p < .0001), plus 112% for the TST (p < .0001) and plus 108% for the CRT (p < .0001). After six months the mean time used for the TUG was decreased by 2.01 s, by 2.29 s for the CRT, and increased by 2.02 s for the TST. Controlled for age, gender, BMI and CrCI, treatment with alfacalcidol for six moths resulted in a significant 48.1% (p _< or = .0001) decrease in the absolute number of fallers and a significant 51.3% (p .0001) decrease in the absolute number of falls, compared to the 6 months prior to alfacalcidol therapy.
Conclusions: Treatment with alfacalcidol increases muscle power and balance as measured with three different muscle power and balance tests and leads to a highly significant decrease in the number of fallers and falls.
Similar articles
-
Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.Arzneimittelforschung. 2011;61(1):40-54. doi: 10.1055/s-0031-1296166. Arzneimittelforschung. 2011. PMID: 21355445
-
Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass.Rheumatol Int. 2012 Jan;32(1):207-15. doi: 10.1007/s00296-010-1607-y. Epub 2010 Sep 9. Rheumatol Int. 2012. PMID: 20827552 Clinical Trial.
-
Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.Arzneimittelforschung. 2011;61(2):104-11. doi: 10.1055/s-0031-1296175. Arzneimittelforschung. 2011. PMID: 21428245
-
The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84. J Musculoskelet Neuronal Interact. 2005. PMID: 16172518 Review.
-
Low creatinine clearance, glucocorticoid treatment, rheumatoid arthritis--different etiologies for low D-hormone syndrome and its associated increased risk for falls.J Rheumatol Suppl. 2005 Sep;76:44-6. J Rheumatol Suppl. 2005. PMID: 16142851 Review.
Cited by
-
Effect of a combination of whole body vibration exercise and squat training on body balance, muscle power, and walking ability in the elderly.Ther Clin Risk Manag. 2014 Feb 20;10:131-8. doi: 10.2147/TCRM.S57806. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 24591837 Free PMC article.
-
Vitamin D deficiency and muscle strength: are they related?J Clin Endocrinol Metab. 2012 Dec;97(12):4366-9. doi: 10.1210/jc.2012-3720. J Clin Endocrinol Metab. 2012. PMID: 23223484 Free PMC article. No abstract available.
-
Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study.J Bone Miner Metab. 2016 Sep;34(5):547-54. doi: 10.1007/s00774-015-0695-x. Epub 2015 Jul 25. J Bone Miner Metab. 2016. PMID: 26209166 Clinical Trial.
-
Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates.Ther Clin Risk Manag. 2014 Jan 16;10:51-9. doi: 10.2147/TCRM.S54772. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 24476669 Free PMC article.
-
Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.Drugs R D. 2014 Dec;14(4):315-24. doi: 10.1007/s40268-014-0069-1. Drugs R D. 2014. PMID: 25480348 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials